6,057 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,057 shares of the medical equipment provider's stock, valued at approximately $374,000.

Other hedge funds have also made changes to their positions in the company. Commonwealth Equity Services LLC increased its stake in Hologic by 1.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 61,958 shares of the medical equipment provider's stock valued at $4,467,000 after purchasing an additional 735 shares during the last quarter. Corient Private Wealth LLC increased its stake in Hologic by 2.9% in the fourth quarter. Corient Private Wealth LLC now owns 53,306 shares of the medical equipment provider's stock valued at $3,843,000 after purchasing an additional 1,518 shares during the last quarter. Signaturefd LLC grew its position in shares of Hologic by 34.5% during the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock worth $212,000 after acquiring an additional 754 shares during the last quarter. Xponance Inc. grew its position in shares of Hologic by 3.3% during the fourth quarter. Xponance Inc. now owns 34,027 shares of the medical equipment provider's stock worth $2,453,000 after acquiring an additional 1,083 shares during the last quarter. Finally, Royal London Asset Management Ltd. grew its position in shares of Hologic by 2.8% during the fourth quarter. Royal London Asset Management Ltd. now owns 344,465 shares of the medical equipment provider's stock worth $24,832,000 after acquiring an additional 9,454 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Insiders Place Their Bets

In other news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Raymond James Financial reissued an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Mizuho boosted their price target on Hologic from $65.00 to $70.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic currently has an average rating of "Hold" and a consensus target price of $77.33.

Hologic Stock Performance

Shares of HOLX stock traded up $0.35 during mid-day trading on Wednesday, reaching $65.72. The stock had a trading volume of 251,166 shares, compared to its average volume of 2,382,793. The firm's 50 day simple moving average is $62.72 and its 200 day simple moving average is $63.07. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The firm has a market cap of $14.65 billion, a PE ratio of 27.71, a P/E/G ratio of 2.33 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business's revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm posted $1.03 EPS. On average, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.